分子生物学
IVD分子诊断
细胞培养与分析
蛋白研究
细胞因子
重组蛋白
抗体
高通量测序建库
病原检测UCF系列
生物医药
工具酶
抑制剂激活剂与常用试剂
仪器
耗材

A strategy of microglia replacement alleviates microgliopathy in a CSF1R I794T hotspot mutation mouse model of CSF1R-related disorder

Xin Li, Banglian Hu, Chujun Wu, Ziwei Wang, Hanzheng Fan, Xiaoyan Guan, Sulan Xie, Dadian Chen, Xiaohua Huang, Hao Sun, Yanfang Li, Xian Zhang, Guojun Bu, Zhanxiang Wang, Yun-Wu Zhang, Li Zhong, Zaiq

Journal:Cell Reports Medicine

IF:14

DOI:10.1016/j.xcrm.2026.102641

PMID:41763216

Published:2026-02-27

research field:神经科学转化医学细胞生物学遗传学分子医学

Abstract

The I794T hotspot mutation in the colony-stimulating factor 1 receptor (CSF1R) gene is associated with primary microgliopathy manifesting as leukoencephalopathy. In this study, we identify three Chinese probands harboring the CSF1R p.I794T variant and characterize their clinical and neuroimaging profiles. To elucidate disease mechanisms and explore therapeutic avenues, we generate a Csf1r I792T/+ knockin mouse model that carries this human mutation. These Csf1r I792T/+ mice exhibit hallmark features of CSF1R-related disorder (CSF1R-RD), including cognitive deficits, ventricular enlargement, reduced microglia, axonal spheroids, and demyelination. Transcriptomic analysis reveals that Csf1r I792T/+ microglia adopt an activated and disease-associated microglia (DAM)-like phenotype. Crucially, we develop and test a microglia replacement strategy, termed “duplicate-cyclic microglial depletion for transplantation” (DCMDT), which significantly ameliorates neuropathological deficits in Csf1r I792T/+ mice. Our findings highlight the pathological significance of the CSF1R p.I794T mutation and propose DCMDT as a promising therapeutic approach for neurodegenerative disorders driven by microglial dysfunction.

本文使用的Yeasen产品

购物车
客服
转染试用